台康生技 News Releases

Tai康 Biotech Announces Expanded NHI Coverage for Biosimilar Drug 'Yikangping Lyophilized Injection 420mg (EIRGASUN vial 420mg)' Starting July 1

Tai康 Biotech announced the expansion of national health insurance coverage for its biosimilar drug E… · 2026-06-16

[EirGenix] Announcement on Completion of Capital Reduction Registration for Cancelled Restricted Employee Shares

EirGenix has announced the completion of capital reduction registration following the cancellation o… · 2026-05-29

[EirGenix] Announcement of the Resolution of the Shareholders' Meeting Regarding the Lifting of Non-Compete Restrictions for Directors and Representatives

EirGenix held its shareholders' meeting on May 29, 115, and approved the lifting of non-compete rest… · 2026-05-29

[EirGenix] Important Resolutions of the Annual General Meeting

EirGenix held its Annual General Meeting on May 29, 115, approving the 114th fiscal year loss compen… · 2026-05-29

[EirGenix] The company's biosimilar drug "EIRGASUN vial 420 mg" approved by the NHIA for National Health Insurance coverage

EirGenix's biosimilar drug EIRGASUN (for breast and stomach cancer) has been approved for NHI covera… · 2026-05-15

[EirGenix] The company's biosimilar drug "EIRGASUN vial 420 mg" approved by the NHIA for National Health Insurance coverage

EirGenix's biosimilar drug EIRGASUN (for breast and stomach cancer) has been approved for NHI covera… · 2026-05-15

[EirGenix] Announcement of interim board resolution to repurchase treasury shares

EirGenix announced on May 14, 2026, that its interim Board of Directors has resolved to repurchase t… · 2026-05-14

[EirGenix] Announcement of interim board resolution to repurchase treasury shares

EirGenix announced on May 14, 2026, that its interim Board of Directors has resolved to repurchase t… · 2026-05-14

TaiCon Bio Announces Board Approval of Q1 2026 Consolidated Financial Report

TaiCon Bio's board of directors approved its consolidated financial report for the first quarter of … · 2026-05-12

[TaiCang Biotech] The Company's Board of Directors Resolves to Recall and Cancel Restricted Employee Shares That Do Not Meet Vesting Conditions to Adjust Capital

TaiCang Biotech announced the decision to recall and cancel restricted employee shares that did not … · 2026-05-12

[TaiCang Biotechnology] The Company's Q1 2026 Consolidated Financial Report Approved by the Board of Directors

TaiCang Biotechnology announced that its consolidated financial report for the first quarter of 2026… · 2026-05-12

[TaiCang Biotech] The Company's Board of Directors Resolves to Recall and Cancel Restricted Employee Shares That Do Not Meet Vesting Conditions to Adjust Capital

TaiCang Biotech announced the decision to recall and cancel restricted employee shares that did not … · 2026-05-12

ECI Biotechnology Announces Board Meeting Date for Q1 2025 Financial Report on May 12, 2026

ECI Biotechnology has announced that its board meeting to review the Q1 2025 financial report will b… · 2026-05-04

ECI Biotechnology Announces Board Meeting Date for Q1 2025 Financial Report on May 12, 2026

ECI Biotechnology has announced that its board meeting to review the Q1 2025 financial report will b… · 2026-05-04

[EirGenix] May 2026 Revenue Reaches NT$ 117 Million (+56.3% YoY)

Taiwanese biotech company EirGenix announced its May 2026 revenue of NT$ 116.8 million (NT$ 116,798 … · 2026-05-01

TaiCom Biotech Invited to Participate in E.SUN Securities Corporate Briefing

TaiCom Biotech announced its participation in a corporate briefing hosted by E.SUN Securities on Apr… · 2026-04-29

TaiCom Biotech Invited to Participate in E.SUN Securities Corporate Briefing

TaiCom Biotech announced its participation in a corporate briefing hosted by E.SUN Securities on Apr… · 2026-04-29

[EirGenix] Licensing Partner Sandoz Submits Variation Application to EMA for EG12014 to Add 420mg Vial Dosage

EirGenix announced that its partner Sandoz has submitted a Type II variation application to the EMA … · 2026-04-24

[EirGenix] Licensing Partner Sandoz Submits Variation Application to EMA for EG12014 to Add 420mg Vial Dosage

EirGenix announced that its partner Sandoz has submitted a Type II variation application to the EMA … · 2026-04-24

【Tai Kang Biotech】2026-04 Monthly Revenue NT$0.082 Billion (YoY -15.8%)

Tai Kang Biotech announced its monthly revenue for April 2026 was NT$0.082 billion (approximately NT… · 2026-04-01

【Tai Kang Biotech】2026-04 Monthly Revenue NT$0.082 Billion (YoY -15.8%)

Tai Kang Biotech announced its monthly revenue for April 2026 was NT$0.082 billion (approximately NT… · 2026-04-01

TaiGen Biotechnology: March 2026 Revenue Reaches 115 Million Yuan (Up 28.2% Year-on-Year)

TaiGen Biotechnology announced its March 2026 revenue of 115 million yuan, marking a significant 28.… · 2026-03-01

TaiGen Biotechnology: March 2026 Revenue Reaches 115 Million Yuan (Up 28.2% Year-on-Year)

TaiGen Biotechnology announced its March 2026 revenue of 115 million yuan, marking a significant 28.… · 2026-03-01

【EirGenix】February 2026 Revenue: NT$85M (YoY +100.6%)

EirGenix, Inc. has released its financial report for February 2026, posting a monthly revenue of NT$… · 2026-02-01

【EirGenix】February 2026 Revenue: NT$85M (YoY +100.6%)

EirGenix, Inc. has released its financial report for February 2026, posting a monthly revenue of NT$… · 2026-02-01